BioInvent International
Björn Frendéus is the current Chief Scientific Officer at BioInvent International. Prior to their current position, Frendéus served as the Chair of the Infection Biology Expert Reviewer Committee at SSF Swedish Foundation for Strategic Research from August 2015 to January 2019. Björn also served as an Expert Reviewer for The Swedish Foundation for Strategic Research's 200 million SEK call "Molecular mechanisms in the interplay between microorganisms/parasites and their hosts" for proposals for problem- or application-driven research projects of the highest international scientific standard with the aim of stimulating interdisciplinary research collaboration within the Infection biology area, of strategic relevance for the Swedish biopharmaceutical industry, clinical medicine and veterinary medicine as well as Forest/plant breeding industry.
Björn Frendéus has a Ph.D. in Immunology and Microbiology from Lund University in Sweden, and a Master of Science in Molecular Biology from the Natural Sciences Program.
Björn Frendéus reports to Martin Welschof, Chief Executive Officer. They are on a team with Stefan Ericsson - Chief Financial Officer, Marie Moores - Chief Operating Officer, and Kristoffer Rudenholm Hansson - Senior Vice President, Technical Operations.
This person is not in any offices
BioInvent International
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.